American Heart Technologies

What American Heart Technologies does

American Heart Technologies LLC is a private, founder-controlled medical device and preventive healthcare technology company headquartered in Palo Alto, California, with research facilities in Torrance (at the Lundquist Institute) and Houston (at the Texas Medical Center). Founded by Dr. Morteza Naghavi, the company operates as a parent holding entity that combines an operating portfolio of six subsidiaries (Endothelix/VENDYS, HeartLung.AI, IC Therapeutics, ThermaRx, LiveLong Health, and DrMe.AI) with a venture investment arm called MEDITEX Capital. The portfolio spans FDA-cleared medical devices, AI-powered diagnostic platforms, ischemic conditioning therapies, and consumer-facing home health technologies, all oriented around shifting cardiovascular and pulmonary care from late-stage symptomatic medicine to early-stage preventive detection.

The company's core technology base combines machine learning, deep learning, and robotics to deliver non-invasive, operator-independent diagnostic and therapeutic systems. The flagship VENDYS platform (Endothelix subsidiary) is an FDA-cleared digital thermal monitoring device that measures endothelial function through fingertip temperature changes during arm-cuff occlusion and is distributed to cardiology, internal medicine, and wellness clinics in the US and Europe. HeartLung.AI applies deep learning to chest CT scans to detect coronary artery calcium and lung cancer, with collaborative validation from Stanford, Mount Sinai, UCLA, Cornell, and Emory. The proprietary ML heart attack prediction model was developed in collaboration with Stanford, Mount Sinai, and UCLA and demonstrated superiority over the ACC/AHA CVD Risk Calculator in the MESA study. Additional portfolio technologies include ischemic conditioning devices for replicating exercise benefits, automated self-administered painless blood drawing, and heat-delivery therapeutics for heart failure.

The business model combines hardware sales of FDA-approved medical devices to specialty clinics, technology licensing of patented medical technologies, venture returns from portfolio investments, and an active investor/entrepreneur outreach program via MEDITEX Capital. Customer segments span cardiology and internal medicine clinics, wellness clinics, primary care offices, and individual consumers for home-based diagnostics. The company pursues a sales-led, enterprise field sales motion targeting healthcare institutions, with a stated strategic intent to expand distribution from hospitals and specialty clinics into primary care offices and patients' homes. Most pricing is not publicly disclosed, and the company solicits healthcare investors and med-tech entrepreneurs through direct outreach to [email protected].

Name

American Heart Technologies

Legal name

American Heart Technologies LLC

Website

https://americanhearttechnologies.com

Company type

Private

Operating status

Operating

Short description

American Heart Technologies LLC is a private medtech holding company that develops FDA-cleared cardiovascular diagnostic devices and AI-powered early detection platforms for heart disease and lung cancer, targeting cardiology and internal medicine clinics, primary care offices, and home-based consumers in the US and Europe.

Ownership category

akta.pro rank

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

akta.pro secondary industries

Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• Cardiovascular medical devices
• Endothelial function monitoring
• Preventive healthcare technology
• AI medical diagnostics
• Ischemic conditioning therapy

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Medical Device Sales: Sale of FDA-approved medical devices including VENDYS endothelial function monitoring system to cardiology, internal medicine, and wellness clinics in the US and Europe
2. Investment Returns: Returns from portfolio companies through venture capital investments and successful exits (e.g., Volcano Corp acquired by Philips for $1.2B)
3. Technology Licensing: Licensing of patented medical technologies including ischemic conditioning devices and AI-powered diagnostic platforms
4. Investment Capital: MEDITEX investment arm seeks to invest in innovative healthcare technologies with potential to improve lives while achieving financial success

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

American Heart Technologies develops and markets FDA-approved medical devices and AI-powered preventive healthcare technologies. Its primary offerings include the VENDYS endothelial function monitoring system (marketed to cardiology, internal medicine, and wellness clinics), AI diagnostic platforms for early detection of heart disease and lung cancer (HeartLung.AI), ischemic conditioning therapy devices (IC Therapeutics, ThermaRx), and in-development consumer-facing AI medical consultation platforms (DrMe.AI, LiveLong Health). The company operates these through a portfolio of subsidiaries and partnerships under its investment arm MEDITEX.

Product overview

American Heart Technologies operates a multi-product portfolio focused on preventive healthcare and cardiovascular disease detection. The company offers both FDA-cleared medical devices (Endothelix/VENDYS-II for endothelial function monitoring) and AI-powered platforms (HeartLung.AI for early detection of heart disease and lung cancer, DrMe.AI for personalized medical consultation). Additional products include IC Therapeutics for ischemic conditioning, ThermaRx for heat-based therapy, and LiveLong Health for AI-powered consumer-centric home healthcare. The portfolio spans from hospital/specialty clinic use to primary care offices and patients' homes, incorporating machine learning, deep learning, and robotics to shift care from sick care to preventive personalized medicine.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Machine learning system outperforms ACC/AHA CVD Risk Calculator in MESA study for predicting cardiovascular events
• +2 more outcomes

Segments5 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Stanford UniversitycoreStrategic or Co-development PartnerCollaborative research partner in Machine Learning Vulnerable Patient Project for development of artificial intelligence for prediction of near-future heart attacks
• Mount Sinai Medical CentercoreStrategic or Co-development PartnerCollaboration on machine learning heart attack prediction project; Dr. Javier Zulueta serves on HeartLung medical leadership team; Dr. Henschke and Dr. Yankelevitz from Mount Sinai collaborated on NIH grant application
• UCLAcoreStrategic or Co-development PartnerResearch collaborator in Machine Learning Vulnerable Patient Project for development of AI for heart attack prediction
• Panasonic HealthminorStrategic or Co-development PartnerCollaborated with CardioNexus Corporation to build the CardioHealth Station, a multi-modality all-in-one device. Project did not reach mass production.
• Texas Heart InstitutecoreStrategic or Co-development PartnerDr. Naghavi was trained as a cardiovascular physician scientist at the Texas Heart Institute under distinguished cardiologists Dr. Ward Casscells and Dr. James Willerson
• Cornell UniversitycoreStrategic or Co-development PartnerDr. Anthony Reeves, professor of engineering and computer science, collaborates on automatic detection of coronary artery calcium score and heart disease using CT scans with Dr. Naghavi and Dr. Budoff
• Emory University School of MedicinecoreStrategic or Co-development PartnerDr. Dong Li, cardiovascular epidemiologist and AI pioneer, collaborates on AI applications in diagnostic medical imaging research
• University of HoustoncoreStrategic or Co-development PartnerDr. Stanley Kleis collaborated with Dr. Naghavi on development of VENDYS endothelial function monitoring technology; research on fluid mechanics and bioreactors
• SHAPE (Society for Heart Attack Prevention and Eradication)coreStrategic or Co-development PartnerNonprofit organization founded by Dr. Naghavi focused on innovative solutions for eradication of heart attacks; led to new CVD risk assessment guidelines and CAC scoring recommendations

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• HeartFlow: HeartFlow provides AI-powered, non-invasive cardiovascular diagnostic analysis (FFR-CT) used by cardiologists to assess coronary artery disease — a directly comparable AI-based cardiac diagnostic that competes with HeartLung.AI's CT-based coronary calcium detection and with the broader preventive cardiology positioning of VENDYS.
• Cleerly Health: Cleerly applies AI to coronary CT angiography for cardiovascular disease assessment and prevention, mirroring HeartLung.AI's deep learning approach to CAC scoring and early heart disease detection on chest CTs.
• iRhythm Technologies: iRhythm makes FDA-cleared cardiac monitoring devices and AI-powered arrhythmia detection (Zio), a direct comparable to VENDYS as an FDA-cleared outpatient cardiac diagnostic tool sold to cardiology clinics.
• AliveCor: AliveCor produces KardiaMobile, an FDA-cleared consumer/cardiologist-facing ECG device and AI platform for cardiac monitoring — directly comparable to American Heart Technologies' strategy of moving cardiac diagnostics from clinics to homes via FDA-cleared devices.
• Eko Health: Eko Health builds AI-powered digital stethoscopes and cardiac monitoring tools used by clinicians, with FDA-cleared hardware and AI algorithms — a direct peer in FDA-cleared AI cardiac diagnostics sold into cardiology and primary care.

Emerging players

• Cardio Diagnostics Holdings: Cardio Diagnostics combines AI with epigenetics and genetic biomarkers for cardiovascular disease detection — an emerging player in AI-driven preventive cardiology with similar target customers (primary care, cardiology) and value proposition.
• Elucid Bioimaging: Elucid uses AI-based image analysis for cardiovascular disease characterization from non-invasive imaging — comparable to HeartLung.AI's use of deep learning on CT scans for early CV disease detection.

Broad incumbents

• Philips Healthcare: Philips is the acquirer of Volcano Corp (the founder's prior $1.2B exit) and operates broadly in cardiovascular imaging, monitoring, and AI diagnostics — a broad incumbent likely to evaluate American Heart Technologies as an acquisition target.
• GE HealthCare: GE HealthCare provides broad cardiology imaging and AI-enabled diagnostic platforms across hospital systems globally, representing a competitive incumbent in CV imaging and a potential strategic acquirer of specialized CV AI/diagnostic technology.

Others

• CardioNexus Corporation: CardioNexus is an existing collaborator of American Heart Technologies (Panasonic partnership) focused on multi-modality CV diagnostic devices — listed as an 'others' category peer because the relationship is enabling/ecosystem rather than directly competitive.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/american-heart-technologies

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about American Heart Technologies